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Background: Trigeminal-mediated headshaking results from low-threshold firing of the trigemi-
nal nerve resulting in apparent facial pain. Magnesium may have neuroprotective effects on
nerve firing that potentially dampen signs of neuropathic pain. This hypothesis has not been
investigated in horses with trigeminal-mediated headshaking.
Objective: To investigate head-shaking behavior in affected horses after IV magnesium sulfate
infusion.
Animals: Six geldings with trigeminal-mediated headshaking.
Methods: Prospective randomized crossover study. Horses were controlled for diet and infused
IV with 5% dextrose solution (DS; control solution at 2 mL/kg body weight [BW]) and MgSO4
50% solution (MSS at 40 mg/kg BW). Head-shaking behavior was recorded at times T0 (base-
line, before infusion) and T15, T30, T60, and T120 minutes post-infusion. Venous blood vari-
ables such as pH, HCO3
−, standard base excess (SBE), Na+, Cl−, K+, Ca2+, Mg2+, total magnesium
(tMg), glucose, and lactate were measured; strong ion difference (SID) and anion gap (AG) were
calculated for each time point.
Results: Blood variables including pH, Na+, Cl−, K+, SID, AG, lactate, Ca2+, tMg, and Mg2+ had
significant changes with MSS as compared to DS treatment. Glucose, SBE, and HCO3
− did not
have significant changes. A 29% reduction in head-shaking rate occurred after MSS treatment
but no change occurred after DS treatment.
Conclusions and Clinical Importance: Administration of MSS IV increased plasma total and ion-
ized magnesium concentrations and significantly decreased head-shaking behavior in horses
with trigeminal-mediated headshaking.
KEYWORDS
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1 | INTRODUCTION
Trigeminal-mediated headshaking in horses is a disorder associated
with a decreased threshold of firing of the trigeminal nerve leading to
apparent episodic intractable facial pain, compromised performance
and quality of life, and ultimately leading to euthanasia of severely
affected horses thus representing a major welfare concern.1,2 This
disorder is manifested as violent, mostly vertical, head shakes, and
other common signs including apparent pruritus, tingling, and pre-
sumed burning or electric-like sensation in the horse's face, similar to
that described for neuropathic pain in people.1–8 Horses may snort,
rub their nose on their limbs, or attempt to strike at their face with
their thoracic limbs in attempts to get relief.3 Studies on somato-
sensory nerve conduction of the trigeminal nerve indicated at least a
10-fold lower threshold to trigger nerve conduction of the maxillary
Abbreviations: AG, anion gap; BW, body weight; DS, dextrose solution group;
MSS, MgSO4 solution; tMg, total magnesium; SBE, standard base excess; SID,
strong ion difference.
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branch of the trigeminal nerve in affected horses compared to control
horses.1,2 Results from such studies described a functional rather than
anatomical abnormality, hence the name trigeminal-mediated head-
shaking.1,9,10 This disorder has been reported in young, mature horses
of several breeds, with a predominance of cases in geldings (72%).3,5,6
Head-shaking behavior appears to have a seasonal predominance in
60% of horses, with peaks during the spring and summer months.3
Various treatments have been attempted, including nose nets, ultra-
violet protective masks, nutritional supplements, drug treatment, nerve
blocks, neurectomy or nerve compression, and electrical neuromodula-
tion of the infraorbital nerve, but results have been inconsistent.11–17
Anecdotally, magnesium supplementation leads to a decrease in
head-shaking signs in 40% of affected horses.9,18 Magnesium is the
second most abundant intracellular cation, and it participates in >300
biochemical reactions including ATPase-dependent ion pumps.19,20
Intracellular and extracellular fluid magnesium concentrations play a
role in the transmission of nerve impulses and might result in neuro-
protective effects.21–24 Intravenous infusion of MgSO4 has many uses
in horses, including treatment for hypomagnesemia, and decreasing
intraoperative and postoperative pain. It also has been used in humans
as a treatment for neuropathic pain with variable results.4,19,23,25–27
Horses affected by trigeminal-mediated headshaking do not show
signs of hypomagnesemia, although 50%-60% of affected horses may
have ionized magnesium (Mg2+) concentrations below the reference
range.28 The objective of our study was to investigate the effect of
an IV infusion of magnesium on head-shaking behavior in horses
with trigeminal-mediated headshaking. Infusion of MgSO4 would be
expected to temporarily increase blood magnesium concentra-
tions.25,27 We hypothesized that the infusion of MgSO4 would
increase total (tMg) and ionized (Mg2+) magnesium concentrations in
the blood and decrease head-shaking behavior.
2 | MATERIALS AND METHODS
2.1 | Animals
Six geldings with naturally occurring head shaking donated to the
Center for Equine Health were included in the study. Inclusion criteria
consisted of fulfillment of the diagnosis of trigeminal-mediated head-
shaking by exclusion of all other known causes of head shaking as
described elsewhere.9 Horses included were Quarter Horses (n = 4)
and Thoroughbreds (n = 2), aged 5-13 years, and weighing between
472 and 580 kg. At the time of donation, horses had received all
recommended vaccinations and deworming as per the Center for
Equine Health protocols. These horses were known to be seasonal
head shakers and had been donated because they were refractory to
various treatments including antihistamines for possible allergies.
These horses displayed head-shaking behavior at the time of the
study. The horses underwent thorough physical and neurologic exami-
nations performed by a board-certified large animal internist and neu-
rologist, followed by a thorough diagnostic investigation. Diagnostic
evaluation included oral, ophthalmic, and otoscopic examinations,
CBC, serum biochemical profile, skull radiographs, and upper airway
endoscopy including evaluation of the guttural pouches. Furthermore,
none of the horses had apparent cervical or nuchal pain based on pal-
pation, extension, and flexion of the neck that could have contributed
to head-shaking behavior. Computed tomography of the head to elim-
inate other causes was not performed. Based on historical seasonal
head shaking, observed head-shaking behavior by the authors during
spring and summer, and lack of abnormal findings on various diagnos-
tic modalities, the authors believed that all of these features
supported a clinical diagnosis of trigeminal-mediated headshaking.
Furthermore, it is unlikely that these horses would have had abnor-
malities manifested in an intermittent fashion during spring and sum-
mer months. Horses were housed in 5 × 12 ft covered stalls that
contained automatic watering devices (water provided free choice)
and raised metal bins for hay. Horses were fed twice daily at 7:00 AM
and 5:00 PM. Stalls were cleaned and bedded with shavings daily.
2.2 | Experimental design
The study had a randomized, controlled crossover experimental
design, in which each horse served as its own control. The horses
were randomized to 1 of the 2 treatment groups, with a washout
period of >1 week between treatments. The entire study took place
over 5 weeks in the early summer to avoid seasonal and environmen-
tal variability. All horses received both treatments. An IV catheter was
placed in the left jugular vein using aseptic technique. Horses received
sterile fluids IV: the Dextrose Solution (DS) group received 5% dex-
trose solution at 2 mL/kg body weight (BW), and the Magnesium
Sulfate Solution (MSS) group received 50% MgSO4 solution at
40 mg/kg BW diluted in 5% dextrose solution. The infusion time was
5-10 minutes, and after infusion the catheter was removed.
2.3 | Sample collection
Heparinized blood samples were collected by venipuncture from the
right jugular vein at T0 (baseline, before infusion) and T5, T15, T30,
T60, and T120 minutes post-infusion and placed on ice immediately.
2.4 | Blood analysis
Venous blood pH, standard base excess (SBE), HCO3
−, Na+, Cl−, K+,
Ca2+, lactate and glucose concentrations were determined using an
ABL815 FLEX (Radiometer America Inc, Brea, California). Total magne-
sium (tMg) and ionized magnesium (Mg2+) concentrations were deter-
mined using a NOVA 8 (NOVA Biomedical, Waltham, Massachusetts).
Strong ion difference (SID) was calculated using the Stewart equation
as follows: [(Na+ + K+ + Ca2+ + Mg2+) − (Cl−)].26 Anion gap (AG) was cal-
culated using the equation as follows: [(Na+ + K+) − (Cl− + HCO3−)].26
2.5 | Behavioral analysis
Horses were placed in individual round pens and evaluated by 3 inde-
pendent, trained evaluators for head-shaking behavior while at a walk
(1 minute), trot (1-3 minutes), canter (1 minute), and walk again
(1 minute) and at 5 time points, T0 (before infusion), T15, T30, T60,
and T120 minutes post-infusion. This protocol was selected because
light exercise in this group of horses resulted in exacerbation of signs as
seen in a previous pilot study. After each time point, horses were
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returned immediately to their stalls. Evaluators were unaware of which
treatment each horse received on any particular day. The head-shaking
behavior (including head shakes [vertical head shakes]/minute, head-
tossing [nonvertical head movements]/minute, nose rubbing/minute,
dropped head/minute, and snorting/minute) was recorded for each
horse during each level of exercise at each time point by the 3 evalua-
tors. A median of each head-shaking behavior per minute for each
horse at each time point during each level of exercise was determined.
Variability among evaluators was evaluated. The study was approved
by our institutional animal care and use committee.
2.6 | Statistical analysis
Data were analyzed using Stata Statistical Software, Release 14 (Stata-
Corp LP 2015, College Station, Texas). For all blood variables, the
results were presented as mean and SD in tabular form and indicated if
within or outside the reference range. A multilevel mixed-effects analy-
sis of variance model also was used to evaluate the main and interactive
effects of treatment groups (DS or MSS) and time (T0, T5, T15, T30,
T60, and T120 minutes post-infusion), with individual horses as random
effect, on blood variables (pH, K+, Na+, Cl−, SBE, HCO3
−, Ca2+, glucose,
lactate, tMg, Mg2+) and calculated values of SID and AG. A P-value <.05
was considered significant. The statistical model utilized in this study
included standard error of the mean for the calculation and representa-
tion of the data for all figures presented here.
For head-shaking behavior, a multilevel mixed-effects Poisson
regression model was used to examine the main and interactive fixed
effects of treatment groups (DS or MSS), time (T0, T15, T30, T60, and
T120 minutes post-infusion), gait and breed, with individual horses as
the random effect, on head shaking. Each gait (first walk, trot, canter,
second walk) was evaluated separately. Within each gait, a model was
created to evaluate the possible interaction between treatment and
time. If the interaction was significant, 2 additional sets of analyses
(effect of treatment at individual times and effect of time within indi-
vidual treatments) were performed. If the interaction was not signifi-
cant, a main effects-only model was fit. Results are presented as
incidence rate ratios (IRR), P-values, and 95% confidence intervals (CI).
A P-value <.05 was considered significant. A plot with the regression
line was used to display longitudinal data for individual horses.
3 | RESULTS
3.1 | Blood results
After the infusion of MSS, Mg2+ peaked at 5 minutes post-
administration and steadily and rapidly decreased over the next time
points, returning nearly to baseline by 120 minutes post-infusion
(Figure 1). Ionized magnesium significantly increased after MSS treat-
ment when compared to DS (+0.20 mmol/L, P < .001, Figure 1).
Ionized and tMg measurements indicated that significant changes
occurred in MSS treatment (P < .001, Figures 1 and 2). Blood variables
including pH, Na+, Cl−, K+, lactate, SID, AG, and Ca2+ were signifi-
cantly different after MSS compared to DS treatment (P < .01,
Figure 3). Glucose, SBE, and HCO3
− did not have significant changes.
At baseline, all blood variables measured were within reference
range with a few exceptions (Tables 1 and 2). Standard base excess
uniformly was above reference range (mean, 6.1 ± 1.2 mmol/L for
DS; 6.5 ± 1.5 mmol/L for MSS; Table 1), and Cl− was above reference
range at baseline (mean, 103 ± 1.7 mmol/L for DS; 103 ± 1.9 mmol/L
for MSS; Table 1). Anion gap was below reference range at baseline
(mean, 7.9 ± 1.8 mmol/L for DS; 4.4 ± 1.8 mmol/L for MSS; Table 2).
Sodium was below reference range in MSS only (mean,
134 ± 3.4 mmol/L; Table 1). For MSS, SID was above reference
range at baseline (mean, 37.7 ± 2.3 mmol/L; Table 2). For MSS, the
baseline measurement for Mg2+ was below reference range (mean,
0.42 ± 0.05 mmol/L; Table 1). Overall, no changes in blood pH,
HCO3
−, and SBE after DS were observed (Table 1).
The DS group experienced a decrease in Na+ at T5 (mean,
134 ± 1.8 mmol/L; Table 1); otherwise, it remained within the refer-
ence range. Serum chloride concentration was above reference range
FIGURE 1 Overall effect of treatment on the blood ionized
magnesium (Mg2+) over time. The mean and SEM venous blood Mg2+
for all 6 horses. Black = DS 5% solution (2 mL/kg BW); gray = MgSO4
50% solution (40 mg/kg BW). BW, body weight; DS, dextrose
solution group; MSS, MgSO4 solution group
FIGURE 2 Overall effect of treatment on the blood total magnesium
(tMg) over time. The mean and SEM venous blood tMg for all 6
horses. Black = DS 5% solution (2 mL/kg BW); gray = MgSO4 50%
solution (40 mg/kg BW). BW, body weight; DS, dextrose solution
group; MSS, MgSO4 solution group
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at baseline and was again above reference range at T30 and T60 (T30
mean, 103 ± 2.2 mmol/L; T60 mean, 103 ± 2.4 mmol/L; Table 1). Blood
glucose concentration was above reference range at T5 and T15 before
returning to reference range (T5 mean, 156 ± 15 mg/dL; T15 mean,
134 ± 16 mg/dL; Table 1). All other blood variables remained within
reference range. Serum osmolality was estimated by equation using
sodium and glucose ([Na+ mmol/L × 2] + [glucose mg/dL/18]). Baseline
mean and SD osmolality was 277 ± 7.0 mOsm/kg (range, 265-286;
reference range, 270-300 mOsm/kg). In the DS group, mean and
SD osmolality was 277 ± 3.6 mOsm/kg (range, 268-283 mOsm/kg),
whereas in the MSS group, the osmolality was 270 ± 4.2 mOsm/kg
(range, 264-278 mOsm/kg).
Infusion of MSS caused a decrease in Na+ at all time points, com-
pared with the DS group. Blood glucose concentration was above ref-
erence range at T5 and T15 before returning to reference range
(T5 mean, 152 ± 9 mg/dL; T15 mean, 133 ± 9 mg/dL; Table 1).
Serum ionized calcium decreased below reference range at T15 and
T30 (T15 mean, 1.39 ± 0.05 mmol/L; T30 mean, 1.38 ± 0.06 mmol/L;
Table 1). Total magnesium concentration increased above reference
range at T5, T15, and T30 (T5 mean, 4.5 ± 0.5 mg/dL; T15 mean,
3.9 ± 0.3 mg/dL; T30 mean, 3.4 ± 0.3 mg/dL; Table 1). Ionized mag-
nesium concentration was below reference range at baseline but
increased above reference range at T5, T15, and T30 before returning
to reference range (T5 mean, 0.99 ± 0.1 mmol/L; T15 mean,
0.86 ± 0.09 mmol/L; T30 mean, 0.74 ± 0.09 mmol/L; Table 1).
3.2 | Behavior results
Head-shaking behavior, which included head shakes/minute, head-
tossing/minute, nose rubbing/minute, dropped head/minute, and
snorting/minute, varied widely among horses. For statistical analysis,
we focused on head shakes/minute because it was the most impor-
tant and consistent behavior of affected horses. The range of head
shakes/minute among horses varied widely, because some horses
were very severely affected (eg, baseline at trot 11 head shakes/
minute and at canter 26 head shakes/minute), whereas other
behaviors were not. Nonetheless, overall head-shaking behavior was
altered by the infusion of MgSO4. Longitudinal data for individual
horses can be found in Figure 4.
A mixed-effects Poisson regression model evaluated the effects of
treatment and time while controlling for breed and gait on median head
shakes/minute. An effect of MSS treatment was observed controlling
for time, breed, and gait (first walk, trot, canter, second walk) with a
mean of 0.71 times the rate of head shaking compared to DS group or
a 29% decrease in median head shakes/minute (IRR, 0.710; CI,
0.61-0.82; P < .001; Table 3). When restricted to canter, the MSS
group experienced 0.49 times the rate of median head shakes/minute
compared to DS or a 51% decrease in head shaking (IRR, 0.493; CI,
0.40-0.61; P < .001; Table 3). There was an effect of trot and DS treat-
ment, while controlling for time and breed, with a 10-fold increase in
median head shakes/minute (IRR, 10.250; CI, 5.66-18.54; P < .001;
Table 4). There was an effect of canter and DS treatment, while con-
trolling for time and breed, with a 22-fold increase in median head sha-
kes/minute (IRR, 22.667; CI, 12.71-40.41; P < .001; Table 4) as
compared to first walk. There was an effect of trot and MSS treatment,
while controlling for time and breed, with a 15-fold increase in median
head shakes/minute (IRR, 15.000; CI, 7.91-28.45; P < .001; Table 4).
There was an effect of canter and MSS treatment, while controlling for
time and breed, with a 13-fold increase in median head shakes/minute
(IRR, 13.400; CI, 7.04-25.48; P < .001; Table 4) as compared to first
walk. There was an effect of time while controlling for treatment, breed,
and gait on median head shakes/minute with T60 having 0.77 times
the rate of head shaking as compared to T0 or a 24% decrease in head
shaking (IRR, 0.765; CI, 0.60-0.96; P = .02). There was an effect of time
when restricted to DS treatment and controlling for gait and breed with
a 37% increase in median head shakes/minute at T120 (IRR, 1.367; CI,
1.02-1.83; P = .04; Table 5). There was an effect of time at T30 when
restricted to MSS treatment and controlling for gait and breed with
0.64 times the rate of head shaking as compared to T0 or a 36%
decrease in head shaking (IRR, 0.644; CI, 0.46-0.90; P = .01; Table 5).
There was an effect of time at T60 when restricted to MSS treatment
and controlling for gait and breed with 0.47 times the rate of head
shaking compared to T0 or a 53% decrease in head shaking (IRR, 0.471;
CI, 0.33-0.68; P < .001; Table 5). There was an effect of time at T120
when restricted to MSS treatment and controlling for gait and breed
with 0.48 times the rate of head shaking as compared to T0 or a 52%
decrease in head shaking (0.483 IRR; CI, 0.33-0.69, P < .001, Table 5).
Thoroughbreds had a numerically greater reduction in head shakes per
minute in response to MSS treatment compared to Quarter Horses, but
the limited number of animals of each breed in the study did not permit
statistical comparison.
There was a significant interaction between treatment and time
while controlling for treatment, gait, and breed with MSS and T30
having 0.62 times the rate of head shaking compared to DS and T0 or
a 38% decrease in head shaking (IRR, 0.620; CI, 0.39-0.98; P = .04).
There was a significant interaction between treatment and time while
controlling for treatment, gait, and breed with MSS and T60 having
0.43 times the rate of head shaking compared to DS and T0 or a 57%
decrease in head shaking (IRR, 0.432; CI, 0.27-0.70; P = .001). There
was a significant interaction between treatment and time while con-
trolling for treatment, gait, and breed with MSS and T120 having 0.35
FIGURE 3 Overall effect of treatment on the blood ionized calcium
(Ca2+) over time. The mean and SEM venous blood Ca2+ for all 6
horses. Black = DS 5% solution (2 mL/kg BW); gray = MgSO4 50%
solution (40 mg/kg BW). BW, body weight; DS, dextrose solution
group; MSS, MgSO4 solution group
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TABLE 1 Changes in blood variables after IV infusion of DS and MSS. DS, 5% dextrose solution (2 mL/kg BW) and MSS, MgSO4 50% solution
(40 mg/kg BW) in 5% dextrose
Treatments
DS MSS
Blood variable Mean SD Mean SD
pH (ref 7.35 to 7.45)
0 7.375 ±0.021 7.390 ±0.017
5 7.402 ±0.015 7.393 ±0.014
15 7.388 ±0.015 7.395 ±0.007
30 7.403 ±0.022 7.400 ±0.023
60 7.425 ±0.014 7.397 ±0.013
120 7.413 ±0.021 7.397 ±0.006
SBE mmol/L (ref −3.0 to +3.0)
0 6.1 ±1.2 6.5 ±1.5
5 5.7 ±1.4 5.6 ±1.1
15 6.0 ±1.2 6.3 ±0.8
30 6.5 ±1.5 6.7 ±1.3
60 7.1 ±1.9 6.0 ±1.2
120 6.5 ±1.5 6.0 ±1.2
HCO3
− mmol/L (ref 25 to 32)
0 31.1 ±1.3 31.4 ±1.5
5 30.4 ±1.4 30.4 ±1.2
15 30.9 ±1.1 31.1 ±0.9
30 31.3 ±1.5 31.5 ±1.4
60 31.5 ±2.1 30.7 ±1.2
120 31.1 ±1.6 30.7 ±1.4
Na+ mmol/L (ref 135 to 145)
0 138 ±2.2 134 ±3.4
5 134 ±1.8 131 ±2.3
15 135 ±1.8 132 ±2.4
30 136 ±1.9 133 ±2.2
60 136 ±1.6 133 ±1.9
120 136 ±2.4 132 ±1.5
Cl− mmol/L (ref 94 to 102)
0 103 ±1.7 103 ±1.9
5 101 ±1.6 101 ±1.1
15 102 ±1.8 101 ±2.0
30 103 ±2.2 101 ±2.0
60 103 ±2.4 101 ±1.9
120 102 ±2.7 101 ±1.9
K+ mmol/L (3.3 to 5.0)
0 4.4 ±0.8 4.3 ±1.0
5 4.9 ±0.7 4.3 ±0.5
15 4.8 ±0.8 4.2 ±0.5
30 5.0 ±0.7 4.2 ±0.3
60 4.8 ±0.5 4.0 ±0.5
120 4.3 ±0.6 3.8 ±0.4
Glucose mg/dL (ref 77 to 110)
0 91 ±8 96 ±7
5 156 ±15 152 ±9
15 134 ±16 133 ±9
30 98 ±16 103 ±15
60 89 ±4 89 ±8
120 92 ±6 89 ±6
(Continues)
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times the rate of head shaking compared to DS and T0 or a 65%
decrease in head shaking (IRR, 0.353; CI, 0.22-0.56; P < .001). There
was a significant interaction between treatment and time while
restricted to the trot, with MSS and T60 having 0.42 times the rate of
head shaking compared to DS and T0 or a 58% decrease in head shak-
ing (IRR 0.416; CI 0.19-0.93; P = .03). There was a significant interac-
tion between treatment and time while restricted to the trot, with
MSS and T120 having 0.45 times the rate of head shaking compared
to DS and T0 or a 55% decrease in head shaking (IRR, 0.451; CI
0.22-0.95; P = .04). There was a significant interaction between treat-
ment and time while restricted to the canter, with MSS and T60 hav-
ing 0.40 times the rate of head shaking compared to DS and T0 or a
60% decrease in head shaking (IRR, 0.404; CI 0.21-0.80; P = .009).
There was a significant interaction between treatment and time while
restricted to the canter, with MSS and T120 having 0.20 times the
rate of head shaking compared to DS and T0 or an 80% decrease in
head shaking (IRR, 0.200; CI, 0.09-0.44; P < .001). There were no sig-
nificant interactions between treatment and gait. There were no sig-
nificant interactions between treatment and breed.
3.3 | Agreement between evaluators
Spearman's correlation was used to assess interobserver variability
among the 3 evaluators. There was a strong agreement between
observer 1 and 2 (rs = 0.94; P < .0001), observer 1 and 3 (rs = 0.84;
P < .0001), and observer 2 and 3 (rs = 0.88; P < .0001).
4 | DISCUSSION
We evaluated the effects on head-shaking behavior of IV administra-
tion of MSS. These effects were expected to be observed over a
short time frame because of the blood and tissue distribution of the
solutions after a single infusion. The MSS treatment induced a 29%
decrease in median head shakes/minute when compared to DS across
all gaits (first walk, trot, canter, second walk). As exercise intensity
increased from walk to trot to canter, median head shakes/minute
also increased, suggesting that exercise might have contributed to the
triggering or exacerbation of the observed signs in horses affected
with trigeminal-mediated headshaking. Similar observations have been
TABLE 1 (Continued)
Treatments
DS MSS
Blood variable Mean SD Mean SD
Lactate mmol/L (ref < 2)
0 0.8 ±0.1 0.9 ±0.5
5 1.0 ±0.2 0.8 ±0.2
15 1.1 ±0.3 0.7 ±0.1
30 0.9 ±0.2 0.8 ±0.2
60 0.9 ±0.3 0.6 ±0.2
120 1.1 ±0.6 0.7 ±0.2
Ca2+ mmol/L (ref 1.40 to 1.60)
0 1.60 ±0.05 1.52 ±0.05
5 1.59 ±0.04 1.44 ±0.05
15 1.57 ±0.05 1.39 ±0.05
30 1.54 ±0.03 1.38 ±0.06
60 1.55 ±0.05 1.40 ±0.05
120 1.57 ±0.07 1.44 ±0.03
tMg mg/dL (ref 1.9 to 3.0)
0 2.2 ±0.2 2.0 ±0.2
5 2.1 ±0.1 4.5 ±0.5
15 2.1 ±0.1 3.9 ±0.3
30 2.1 ±0.2 3.4 ±0.3
60 2.1 ±0.1 3.0 ±0.2
120 2.1 ±0.2 2.5 ±0.3
Mg2+ mmol/L (ref 0.47 to 0.70)
0 0.51 ±0.09 0.42 ±0.05
5 0.50 ±0.09 0.99 ±0.10
15 0.49 ±0.10 0.86 ±0.09
30 0.48 ±0.09 0.74 ±0.09
60 0.47 ±0.08 0.63 ±0.06
120 0.50 ±0.07 0.54 ±0.04
Numbers in bold for the following variables, Na+, Cl−, K+, glucose, Ca2+, tMg, and Mg2+, indicate values above or below the reference range. Note: For SBE,
the baseline values for all horses were above the reference range. Bold indicates difference from baseline values.
Abbreviations: DS, dextrose solution group; MSS, MgSO4 solution group; SBE, standard base excess; tMg, total magnesium.
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reported anecdotally, and our study results support this assump-
tion.6,18 The largest decrease in head shakes/minute was 51% for the
canter in MSS. The faster the gait, the larger the decrease in median
head shakes/minute after MSS treatment. Therefore, our study high-
lights the possible blunting effects of magnesium during faster gaits
that are likely to exacerbate head-shaking signs. An important finding
is the effect of MSS treatment on decreasing median head shakes/mi-
nute starting at T30 and continuing to T120. This blunting effect
might have persisted longer than our study period of 2 hours. There-
fore, further evaluation to determine how long this blunting effect
persists is warranted. Although there was a larger decrease in the rate
of head shaking in Thoroughbreds compared to Quarter Horses in this
study, the low number of horses per breed precluded any conclusion
with respect to the effect of breed in the response to MSS treatment
in head shaking.
Treatment with MSS supplied a large bolus of magnesium that
should be 100% bioavailable. Potential adverse effects such as sweating,
agitation, muscle fasciculations, arrhythmias, and collapse resulting from
the infusion of MSS were not detected in any of these horses.29
However, the dosage of magnesium used in our study was below that
previously associated with toxicity in horses (1500-2000 mg/kg of
PO MgSO4).
29 Infusion of MSS corrected the lower concentrations of
Mg2+ observed at baseline, which also was seen in a previous study
of horses affected by trigeminal-mediated headshaking.28 The decrease
in head-shaking behavior could be a result of Mg2+ inhibiting nerve
transmission.30 Such inhibition can occur when Mg2+ acts as a blocking
agent to N-methyl-D-aspartate (NMDA) receptors, which have been
shown to have an effect on trigeminal neurons at the trigeminal subnu-
cleus caudalis (ie, the orofacial nociceptive processing center) in rats.30
The NMDA receptors are a subtype of glutamate receptors and, once
activated, are permeable to calcium and other cations.30–32 Magnesium
and zinc can bind to the NMDA receptor and prevent activation.31,32
Magnesium also is involved in the regulation of neuroexcitation and can
inhibit Ca2+-dependent presynaptic excitation-secretion coupling.22
Magnesium also participates in neuromuscular blockade by inhibiting
calcium channels, which inhibits acetylcholine release and muscle excit-
ability.23 Furthermore, magnesium has been utilized in anesthesia as an
analgesic agent.23,33 The exact mechanism of how magnesium acts as a
pain reducer is not known but may involve inhibition of neurotransmis-
sion by blockade of receptors involved in cell excitation.22,31,32 Intrave-
nous magnesium supplementation in our study was expected to have
short-acting effects on magnesium concentrations and head shaking as
fluid distribution occurred in the body. However, magnesium concentra-
tions increased and remained increased 120 minutes after infusion. The
time required for normalization of plasma magnesium concentrations
after infusion was not determined in our study.
Some preexisting differences in baseline blood variables were
present in horses of both treatment groups. These differences might
have reflected individual physiological variations. Significant changes
also occurred in blood Ca2+, pH, K+, Na+, Cl−, SID, AG, and lactate
after administration of treatment solutions. Blood Ca2+ decreased sig-
nificantly in MSS compared to DS. In support of this finding, hypo-
magnesemia has been shown to be induced by hypercalcemia that
occurs after administration of calcium gluconate solution IV.34 Higher
plasma concentrations of Ca2+ activate release of neurotransmitters
and signal the nerve to fire, whereas decreased plasma Ca2+ concen-
trations result in less calcium available for activation of the trigeminal
nerve.35 It has been found that Ca2+ is involved in neuropathic pain of
the trigeminal nerve, which also could be a possible mechanism by
which magnesium treatment resulted in a decrease in head shaking
(decrease in neuropathic pain) in this group of horses.36 Blood sodium
concentrations decreased below reference range in MSS treatment
group. This decrease in Na+ amounted to an average of 4 mmol/L and
occurred concurrently with an increase in blood glucose concentra-
tion. Plasma osmolality was not measured in this study but calculated
using an equation employing Na+ and glucose. Plasma osmolality in
these horses remained within physiologic range after treatment,
despite mild changes in Na+. Because the changes in blood sodium
concentration were mild and transient with treatment, the biological
relevance to clinical manifestations of head shaking were likely mini-
mal. A previous study showed that metabolic alkalosis induced by
administration of hypertonic sodium bicarbonate IV resulted in a
decrease in head-shaking behavior.28
The main limitations of our study included the small number of
horses and lack of control groups (healthy control group [unaffected
horses] and affected untreated horses [no IV solution]). A detailed
diagnostic investigation was done in these horses to eliminate other
causes of head shaking. Computed tomography would have been
helpful to further eliminate other causes but was not performed. Local
anesthesia of the infraorbital nerve was not performed because it is
not specific, and any underlying cause located in areas innervated by
this nerve would have been affected by local anesthesia. Nerve con-
duction velocity studies of the trigeminal nerve would have confirmed
trigeminal-mediated headshaking but would have required general
anesthesia. Therefore, such studies were not performed in these
TABLE 2 Calculated blood results
Treatments
DS MSS
Blood variable Mean SD Mean SD
SID mmol/L (ref 38-42)
0 41.1 ±1.9 37.7 ±2.3
5 39.8 ±1.3 36.9 ±1.9
15 40.2 ±0.9 37.5 ±2.4
30 40.2 ±1.3 38.2 ±2.3
60 40.3 ±1.8 37.4 ±1.2
120 40.2 ±1.2 37.1 ±2.2
AG mmol/L (ref 9-17)
0 7.9 ±1.8 4.4 ±1.8
5 7.4 ±1.2 4.1 ±2.2
15 6.9 ±1.1 4.1 ±2.6
30 6.9 ±1.6 4.5 ±2.1
60 6.7 ±1.5 4.6 ±1.7
120 6.9 ±1.5 4.4 ±1.3
Changes in calculated blood variables after IV infusion of DS and MSS. DS
(5% dextrose solution at 2 mL/kg BW) and MSS (MgSO4 50% solution
(40 mg/kg BW) in 5% dextrose. Numbers in bold indicates values above or
below the reference range for that blood parameter.
Abbreviations: AG, anion gap; DS, dextrose solution group; MSS, MgSO4
solution group; SID, strong ion difference.
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horses. Furthermore, effects of riding, tack, and rider expertise were
not evaluated in our study.
In conclusion, the administration of MSS IV increased tMg and
Mg2+ and significantly decreased head-shaking behavior in horses
with trigeminal-mediated headshaking. Our study supports anecdotal
reports of the perceived benefits of magnesium supplementation
in affected horses. Therefore, future studies should investigate
practical PO supplementation of magnesium with high bioavailability
FIGURE 4 Head-shaking behavior for 6 individual horses and overall change over time. A and B, At the trot. C and D, At the canter. Each horse is
displayed with a different marker, and the overall change in head-shaking behavior is represented by the regression line. Top graphs (A and C) =
DS 5% solution (2 mL/kg BW); bottom graphs (B and D) = MgSO4 50% solution (40 mg/kg BW). BW, body weight; DS, dextrose solution group;
MSS, MgSO4 solution group
TABLE 3 Effect of MSS treatment and gait on IRR of median head
shakes/minute across all times and breeds
Treatment group: MSS
Behavior IRR P value 95% CI
Head shakes
All gaits 0.710 <.001 0.61-0.83
First walk 0.833 .67 0.36-1.93
Trot 1.219 .10 0.96-1.55
Canter 0.493 <.001 0.40-0.61
Second walk 0.499 .06 0.24-1.03
P < .05 was considered significant.
Abbreviations: CI, confidence intervals; IRR, incidence rate ratios;
MSS, MgSO4 solution group.
TABLE 4 Effect of gait (trot and canter) and treatment (DS and MSS)
on IRR of median head shakes/minute across all times and breeds
Treatment IRR P value 95% CI
DS
Trot 10.250 <.001 5.66-18.54
Canter 22.667 <.001 12.71-40.41
MSS
Trot 15.000 <.001 7.91-28.45
Canter 13.400 <.001 7.05-25.48
P < .05 was considered significant.
Abbreviations: CI, confidence intervals; DS, dextrose solution group;
IRR, incidence rate ratios; MSS, MgSO4 solution group.
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for long-term use. Doing so might help address a major welfare chal-
lenge in equine medicine and possibly avoid euthanasia. Further inves-
tigation is warranted to determine if a cutoff concentration of Mg2+
would be associated with the prevention of or decrease in head shak-
ing in affected horses.
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